Stephen Tullman
SlowingNamed in filings at Nexeption CapitalOn the current fund
- Board seats filed
- 8
Named in filings at Nexeption CapitalOn the current fund
all filings on record
last 24 months
from a verified or cited source
| OTH Holding | Biotech & pharma | August 2026 | None on file |
| NexEos Diagnostics | Biotech & pharma | July 2019 | None on file |
| Myota | Cybersecurity | May 2018 | None on file |
| Onspira Therapeutics | Biotech & pharma | June 2017 | None on file |
| Velicept Therapeutics | Biotech & pharma | November 2015 | None on file |
| Zoomi | Education | January 2015 | None on file |
| Aclaris Therapeutics | Biotech & pharma | September 2014 | Aisling Capital, Forest City Enterprises, Sofinnova Venture Partners, Vivo Innovation, Vivo Ventures VII Affiliates |
| Alexar Therapeutics | Biotech & pharma | January 2014 | NSV 2018 New Horizons |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Stephen Tullman on the board, based on 8 filed seats with a verified or cited source.